Nyxoah marked its recent milestones by ringing the Nasdaq Closing Bell, symbolizing the company’s forward momentum as it approaches the potential US market launch of its Genio device for OSA. Summary: Nyxoah SA rang the Nasdaq Closing Bell on Aug 29 to celebrate its … [Read more...]
Nyxoah Prepares Final FDA Module for Genio OSA Neurostimulator
Summary: Nyxoah described its Q1 2024 economic and operating outcomes, highlighting sizeable progress with its Genio program, a leadless and battery-cost-free hypoglossal neurostimulation therapy for obstructive snooze apnea (OSA). The Aspiration US pivotal study reached co-key … [Read more...]
Nyxoah Prepares to Unveil OSA Neurostimulation Study Results
Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea (OSA). The results are expected by early April, according to the company’s fourth-quarter and full-year 2023 … [Read more...]